{"id":811214,"date":"2025-02-10T17:03:34","date_gmt":"2025-02-10T22:03:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/"},"modified":"2025-02-10T17:03:34","modified_gmt":"2025-02-10T22:03:34","slug":"quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/","title":{"rendered":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results"},"content":{"rendered":"<h2>\nPosts Strong Sequential Improvement in Adjusted EBITDA<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CINCINNATI, Feb.  10, 2025  (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201c<strong>Quipt<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Conference Call<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (844) 763-8274 or 1 (647) 484-8814.<\/p>\n<p align=\"justify\">A live webcast of the call will be accessible via the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V2-NfRhvnqxccDGndj8HyuCw3fa0qFOrSZ9oHf2uLGmu2Ka4qdrxwvJA1sp4uUYts1h-V1sYNM_DZ1E1hyABEgDDb9dQwvNRTkNndz29sSkBDkgDyu6qidf8iZUFcPP2N0nv962or5B8NWGalOcF3oZS9zDtiFUC8KNsYQzHsLN523VfuHh04vh_PslZgh-7Wjrqj_0LKXf5877IZh7kHj4KE8wVhLkWVNWT8aODWWTAjDs5j_ne3hIVzjieDnY1xJSR-LS6LaWx9KN60iY4R3Zxb4JRyG8hR4MgXWHgioVe-fbDoCDqKwdooJErPrNwLjKfbSmYD1zsBnMvmBo8GlosC-tihNbhcGPACfjtfFNQUw8PuwaY1N8opBBcgDgWtgnJwhF1w2UE3VhacEqZCBI4ec-yE0fsFdf8k2wm73FP967dld2hKb_TNVmR3KMeHJbs6t2-SDJ2548YKtdeybvB71b-lpVQHPKPm0rgAezlTIzcncGCepcyzdLTwR01\" rel=\"nofollow\" target=\"_blank\">https:\/\/quipthomemedical.com\/investors\/events-presentations\/<\/a>, which will be available on the Company\u2019s website for at least the first year following the event.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Financial Highlights<\/u><br \/>\n        <\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<ul>\n<li>Revenue for Q1 2025 was $61.4 million compared to $62.6 million for Q1 2024, representing a 2% decrease. Revenue for Q1 2025 was flat compared to Q4 2024.\n<ul>\n<li>The Medicare 75\/25 blended rate, which had been providing rate relief for certain geographies, was discontinued as of January 1, 2024\u200e. Although this change is still under legislative review, and could return, its immediate cessation had a negative impact \u200eon our revenue and operating results. Moreover, in certain regions, we also experienced the withdrawal of Medicare Advantage members due to a capitated agreement engaged with other providers in the industry. In November 2024, a disposable supply contract was not renewed. The cumulative annual impact of these three events is estimated to be approximately $8.0 million, with a reduction of approximately $1.5 million for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023.<\/li>\n<\/ul>\n<\/li>\n<li>Net income (loss) improved for Q1 2025 to ($1.1) million, or ($0.03) per diluted share, compared to ($1.5) million, or ($0.04) per diluted share for Q1 2024.<\/li>\n<li>Cash flow from operations was $9.3 million for Q1 2025, compared to $10.6 million for Q1 2024.<\/li>\n<li>The Company reported $15.5 million of cash on hand as of December 31, 2024, compared to $16.2 million as of September 30, 2024. Total credit availability of $32.4 million as of December 31, 2024, with $11.4 million available towards a revolving credit facility and $21 million available pursuant to a delayed-draw term loan facility.<\/li>\n<li>Recurring Revenue<sup>\u200e1<\/sup> for Q1 2025 continues to be strong at 77% of total revenue.<\/li>\n<li>Adjusted EBITDA<sup>1<\/sup> for Q1 2025 was $14.0 million (22.8% of revenue) compared to $15.3 million (24.5% of revenue) for Q1 2024, representing an 8.7% decrease. Adjusted EBITDA<sup>1<\/sup> sequentially increased by 4.5% from Q4 2024, in which the Company reported Adjusted EBITDA<sup>1<\/sup> of $13.4 million (21.8% of revenue).<\/li>\n<li>The Company maintains a conservative balance sheet with Net Debt to Adjusted EBITDA Leverage Ratio<sup>1<\/sup> of 1.5.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Operational Highlights<\/u><br \/>\n        <\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<ul>\n<li>The Company\u2019s customer base increased 1% year over year to approximately 157,000 unique patients served in Q1 2025 from approximately 155,000 unique patients in Q1 2024.<\/li>\n<li>Compared to approximately 215,000 unique set-ups\/deliveries in Q1 2024, the Company completed approximately 221,000 unique set-ups\/deliveries in Q1 2025, an increase of 3%. This includes approximately 124,000 respiratory resupply set-ups\/deliveries for Q1 2025, compared to approximately 123,000 for Q1 2024, an increase of 1%, which the Company credits to its continued use of technology and centralized intake processes.<\/li>\n<li>The Company\u2019s resupply program is a major proponent of the 77% Recurring Revenue<sup>1<\/sup> base as the Company has significantly scaled, now representing 48% of the Recurring Revenue mix, driving higher margin revenue, and now consists of 174,000 patients for the twelve months ended December 31, 2024, compared to 172,000 patients for the twelve months ended September 30, 2024.<\/li>\n<li>Consistent demand and referral patterns across all major product categories.<\/li>\n<li>The Company has approximately 36,000 referring physicians, and over 140 locations.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <sup>1<\/sup> Non-GAAP financial measure or ratio. See \u201cNon-GAAP Financial Measures\u201d below for additional information.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Management Commentary<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\u201cOur fiscal first quarter results reflect the tangible progress we&#8217;ve made in strengthening our operations and positioning the business for long-term growth,\u201d said Gregory Crawford, Chairman and Chief Executive Officer of Quipt. \u201cOur priorities for the fiscal year ending September 30, 2025 and beyond are driving organic revenue growth, achieving operational net profit, generating positive cash flow, and expanding Adjusted EBITDA<sup>1<\/sup>. We are focused on expanding our presence in both existing and new markets and leveraging our scalable business platform to broaden our product offerings and service reach. To support these objectives, we continue to optimize our organizational structure, enhancing operational efficiencies by reducing redundancies, and centralizing back-office processes. These measures are streamlining operations, improving scalability, and positioning the business for sustainable long-term growth. Furthermore, we remain committed to exploring and pursing all avenues to drive shareholder value.\u201d<\/p>\n<p align=\"justify\">\u201cOur financial results highlight the operational enhancements we have made as we continue to optimize our cost structure,\u201d said Hardik Mehta, Chief Financial Officer of Quipt. \u201cThese enhancements are enabling us to operate more efficiently while maintaining our commitment to high-quality patient care. As we continue to execute our strategic growth plans, we expect this operational discipline to support strong margin performance throughout the year. As we look ahead, our balance sheet flexibility and disciplined financial management position us to drive a return towards historical organic growth in calendar 2025 and build long-term shareholder value.\u201d<\/p>\n<p>\n        <strong>ABOUT QUIPT HOME MEDICAL CORP.<\/strong>\n      <\/p>\n<p align=\"justify\">The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company\u2019s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient\u2019s services, and making life easier for the patient.<\/p>\n<p align=\"justify\">\n        <em>Forward-Looking Statements<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Certain statements contained in this press release constitute \u201cforward-looking statements\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or \u201cforward-looking information\u201d as such term is \u200e\u200e\u200e\u200e\u200e\u200edefined in applicable Canadian securities legislation (collectively, \u201cforward-looking statements\u201d). The words \u201cmay\u201d, \u201cwould\u201d, \u201ccould\u201d, \u201cshould\u201d, &#8220;potential\u201d, \u200e\u200e\u200e\u200e\u200e\u200e\u200e&#8221;will\u201d, &#8220;seek\u201d, &#8220;intend\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201coutlook\u201d, or the negatives thereof or variations of such words, and similar expressions \u200e\u200e\u200e\u200e\u200eas \u200ethey relate to the Company, including: the Company anticipating <\/em><br \/>\n        <em>strong margin performance throughout the year and<\/em><br \/>\n        <em> a return to historical organic growth levels<\/em><br \/>\n        <em> in calendar 2025<\/em><br \/>\n        <em>; are intended to \u200eidentify forward-looking information. All statements \u200eother \u200ethan \u200estatements of \u200e\u200ehistorical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-\u200elooking statements<\/em><br \/>\n        <em>and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the \u200eCompany&#8217;s \u200ecurrent \u200eviews and \u200e\u200eintentions with respect to future \u200eevents, and current information available to the \u200eCompany, and \u200eare \u200esubject to \u200e\u200ecertain risks, uncertainties and \u200eassumptions, including, without limitation: the \u200eCompany successfully identifying, \u200e\u200e\u200enegotiating and \u200ecompleting additional acquisitions; operating and other financial metrics maintaining their \u200e\u200ecurrent trajectories, the Company not being impacted by any further external and unique events like the Medicare \u200e\u200e75\/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of the calendar year and in 2025; and the \u200eCompany not being subject to a material change to it cost structure. Many \u200efactors could cause the actual \u200eresults, \u200e\u200eperformance or achievements that may be \u200eexpressed \u200eor implied by such \u200eforward-looking statements to \u200evary from \u200e\u200ethose described herein should one or more \u200eof these \u200erisks or \u200euncertainties materialize. Examples of such \u200erisk \u200efactors \u200einclude, without limitation: risks related \u200eto credit, market \u200e\u200e\u200e(including equity, commodity, foreign exchange \u200eand interest \u200erate), \u200eliquidity, operational \u200e\u200e(including technology \u200eand \u200einfrastructure), reputational, insurance, \u200estrategic, \u200eregulatory, legal, \u200eenvironmental, and \u200ecapital adequacy; the \u200e\u200egeneral business and economic conditions in \u200ethe regions \u200ein which the \u200eCompany operates; \u200ethe ability of the \u200e\u200eCompany to execute on key priorities, including the \u200esuccessful \u200ecompletion of \u200eacquisitions, \u200ebusiness retention, and \u200e\u200estrategic plans and to attract, develop and retain \u200ekey \u200eexecutives; difficulty \u200eintegrating \u200enewly acquired businesses; \u200e\u200ethe ability to implement business strategies and \u200e\u200epursue business opportunities; low \u200eprofit \u200emarket segments; \u200e\u200edisruptions in or attacks (including cyber-attacks) on \u200e\u200ethe Company&#8217;s information \u200etechnology, \u200einternet, network \u200e\u200eaccess or other voice or data communications systems or \u200e\u200eservices; the evolution of \u200evarious types \u200eof fraud or other \u200e\u200ecriminal behavior to which the Company is exposed; the \u200e\u200efailure of third parties to \u200ecomply with \u200etheir obligations to \u200e\u200ethe Company or its affiliates; the impact of new and \u200e\u200echanges to, or application of, \u200ecurrent \u200elaws and regulations; \u200e\u200edecline of reimbursement rates; dependence on few \u200e\u200epayors; possible new drug \u200ediscoveries; a \u200enovel business \u200emodel; \u200edependence on key suppliers; granting of permits \u200e\u200eand licenses in a highly \u200eregulated \u200ebusiness; legal proceedings and litigation, including as it relates to the civil \u200e\u200einvestigative demand (\u201cCID\u201d) \u200ereceived from the Department of Justice; \u200eincreased competition; \u200echanges in \u200eforeign currency rates; \u200eincreased \u200e\u200efunding costs and market volatility due to \u200emarket illiquidity and \u200ecompetition for \u200efunding; the \u200eavailability of funds \u200e\u200eand resources to pursue operations; \u200ecritical accounting \u200eestimates and changes \u200eto accounting \u200estandards, policies, \u200e\u200eand methods used by the Company; the Company\u2019s status as an emerging growth company and a smaller reporting company; the occurrence of \u200enatural and unnatural \u200ecatastrophic \u200eevents or health epidemics or concerns; as well as those risk factors \u200ediscussed or \u200e\u200ereferred to \u200ein the Company\u2019s disclosure \u200edocuments filed with \u200eUnited States Securities and Exchange \u200eCommission \u200e and \u200eavailable at www.sec.gov, including the Company\u2019s most recent Annual Report on Form 10-K, and with \u200ethe securities \u200eregulatory authorities in certain provinces of \u200eCanada and \u200e\u200e\u200eavailable at www.sedarplus.com. Should any \u200efactor affect \u200ethe Company in an unexpected manner, or \u200eshould \u200e\u200e\u200eassumptions underlying the forward-looking \u200estatement prove \u200eincorrect, the actual results or events may \u200ediffer \u200e\u200e\u200ematerially from the results or events predicted. \u200eAny such forward-\u200elooking statements are expressly qualified \u200ein their \u200e\u200e\u200eentirety by this cautionary statement. Moreover, \u200ethe Company \u200edoes not assume responsibility for the \u200eaccuracy or \u200e\u200e\u200ecompleteness of such forward-looking \u200estatements. The \u200eforward-looking statements included in this \u200epress release \u200e\u200e\u200eis made as of the date of this press \u200erelease and the \u200eCompany undertakes no obligation to publicly \u200eupdate or revise \u200e\u200e\u200eany forward-looking statements, \u200eother than as \u200erequired by applicable law\u200e.\u200e<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Non-GAAP Financial Measures<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release refers to \u201cAdjusted EBITDA\u201d, \u201cRecurring Revenue,\u201d and \u201cNet Debt to Adjusted EBITDA Leverage Ratio\u201d, which are non-GAAP financial measures that do not have standardized meanings prescribed by generally accepted accounting principles in the United States (\u201cGAAP\u201d). The \u200eCompany\u2019s presentation of these financial measures may not be comparable to similarly titled measures used by \u200eother companies. These financial measures are intended to provide additional information to investors concerning \u200ethe Company\u2019s performance.\u200e<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision (benefit) for income taxes, professional fees related to CID and loss of foreign private issuer status, stock-based compensation, acquisition-related costs, loss (gain) on foreign currency transactions, change in fair value of derivative liability \u2013 interest rate swaps, and share of loss in equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our GAAP net loss for the \u200efollowing indicated periods\u200e (in $millions)\u200e:\u200e<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:69%;width:69%;min-width:69%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:14%;width:14%;min-width:14%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:14%;width:14%;min-width:14%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>For the three<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>For the three<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>months ended<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>months ended<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>December 31, 2024<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>December 31, 2023<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:67%;min-width:67%;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Net loss<\/em>\n          <\/td>\n<td style=\"max-width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"max-width:14%;min-width:14%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>(1.1<\/em><br \/>\n            <em>)<\/em>\n          <\/td>\n<td style=\"max-width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"max-width:14%;min-width:14%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>(1.5<\/em><br \/>\n            <em>)<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Add back:<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Depreciation and amortization<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>11.0<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>11.2<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Right-of-use operating lease amortization and interest<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>1.5<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>1.5<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Interest expense, net<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>1.6<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>1.6<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Provision for income taxes<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>\u2014<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.2<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Professional fees related to CID<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.4<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.4<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Professional fees related to loss of foreign private issuer status<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.4<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>\u2014<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Stock-based compensation<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.2<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>1.0<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Acquisition-related costs<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>\u2014<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.2<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Change in fair value of derivative liability &#8211; interest rate swaps<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>(1.0<\/em><br \/>\n            <em>)<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.9<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Loss (gain) on foreign currency transactions<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.9<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>(0.3<\/em><br \/>\n            <em>)<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Share of loss in equity method investment<\/em>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.1<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>0.1<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>Adjusted EBITDA<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>14.0<\/em>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>15.3<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <em>Recurring Revenue for Q1 2025 is calculated as rentals of medical equipment of $24.3 million plus sales of respiratory resupplies of $22.9 million for a total of $47.2 million, divided by total revenues of $61.3 million, or 77%.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q4 times four), and is reconciled as follows (in $millions):<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:85%;width:85%;min-width:85%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:14%;width:14%;min-width:14%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>As of and for the\u00a0<br \/><\/em><br \/>\n            <em>three months ended\u00a0<br \/><\/em><br \/>\n            <em>ended December 31,\u00a0<br \/><\/em><br \/>\n            <em>2024<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Senior credit facility, principal<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>70.6<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Equipment loans<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\n            <em>\u00a0<\/em>\n          <\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>12.4<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Lease liabilities<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\n            <em>\u00a0<\/em>\n          <\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>19.0<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Cash<\/em>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\n            <em>\u00a0<\/em>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em> (15.5<\/em><br \/>\n            <em>)<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Net Debt<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em>86.5<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Adjusted EBITDA for Q4 times four<\/em>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\n            <em>$<\/em>\n          <\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em> 56.0<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Net Debt to Adjusted EBITDA Leverage Ratio<\/em>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: top\">\n            <em> 1.5x<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For further information please visit our website at www.Quipthomemedical.com, or contact:<\/p>\n<p>Cole Stevens<br \/>VP of Corporate Development<br \/>Quipt Home Medical Corp.<br \/>859-300-6455<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SzEylb-BFC0MvHXeSp9P8dLxsbhHWAp0Oph7qFTysM34grUF6lonwDSFRa7q3fg3Cso84MufO8xPXWVSDeBlQzNlJWxKvphOzMK3HM3N3n0=\" rel=\"nofollow\" target=\"_blank\">cole.stevens@myquipt.com<\/a><\/p>\n<p>Gregory Crawford<br \/>Chief Executive Officer<br \/>Quipt Home Medical Corp.<br \/>859-300-6455<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SzmcTrMVk3r3s1bo6fGRjviqCacqGouOoeEEaogWw2la5ftdQl0NGaQY7ZHJu-Dq7ewGCCPHB7EktV_FBCE0lNwbisTHsUS8nQKoNud2zlE=\" rel=\"nofollow\" target=\"_blank\">investorinfo@myquipt.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmI3NDhjYzQtNzQyMy00NGYzLTgwMzItM2QyNDI2MWI5NTAwLTEwOTk1NzM=\/tiny\/Quipt-Home-Medical-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Posts Strong Sequential Improvement in Adjusted EBITDA CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201cQuipt\u201d or the \u201cCompany\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (844) 763-8274 or 1 (647) 484-8814. A live webcast of the call will be accessible via the Company\u2019s website at https:\/\/quipthomemedical.com\/investors\/events-presentations\/, which will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-811214","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Posts Strong Sequential Improvement in Adjusted EBITDA CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201cQuipt\u201d or the \u201cCompany\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (844) 763-8274 or 1 (647) 484-8814. A live webcast of the call will be accessible via the Company\u2019s website at https:\/\/quipthomemedical.com\/investors\/events-presentations\/, which will be &hellip; Continue reading &quot;Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-10T22:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results\",\"datePublished\":\"2025-02-10T22:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/\"},\"wordCount\":2051,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/\",\"name\":\"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\",\"datePublished\":\"2025-02-10T22:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk","og_description":"Posts Strong Sequential Improvement in Adjusted EBITDA CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) &#8212; Quipt Home Medical Corp. (\u201cQuipt\u201d or the \u201cCompany\u201d) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (844) 763-8274 or 1 (647) 484-8814. A live webcast of the call will be accessible via the Company\u2019s website at https:\/\/quipthomemedical.com\/investors\/events-presentations\/, which will be &hellip; Continue reading \"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-10T22:03:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results","datePublished":"2025-02-10T22:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/"},"wordCount":2051,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/","name":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=","datePublished":"2025-02-10T22:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTk2OSM2NzQzOTg0IzIwODgwMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quipt-home-medical-reports-first-quarter-fiscal-year-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=811214"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=811214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=811214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=811214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}